Training activity information
Details
Select a sensitised patient and prepare an interpretive report for clinical colleague for investigation of platelet refractoriness
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Considerations
- Protocols for the selection of human leukocyte antigen (HLA) and/or human platelet antigen (HPA) compatible platelets
- Indications for platelet transfusion
- Matching algorithms
- Pre and post transfusion monitoring
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- What is the goal of selecting this patient and preparing this report? How will it aid in the investigation of their platelet refractoriness?
- What is your understanding of platelet refractoriness and its potential causes, including HLA and HPA antibodies?
- What information is relevant to include in an interpretive report for a sensitised patient in this context?
- What specific skills in analysing a patient’s sensitisation profile in relation to platelet transfusion history do you hope to develop?
- How will you learn to identify potential causes of refractoriness based on their antibody profile?
- How will you tailor the interpretive report to provide useful information for clinical colleagues?
- What challenges do you anticipate in correlating antibody data with clinical presentation?
- What patient data will you need to review (e.g., HLA and HPA typing, antibody screening results, platelet transfusion history, increment data if available)?
- Will you consult guidelines on the investigation of platelet refractoriness?
- Will you discuss the case and the required content of the report with your supervisor?
- How do you feel about contributing to the investigation of a complex clinical problem?
In action
- What aspects of the sensitised patient’s history (including transfusion history) are you focusing on?
- What specific HLA and/or HPA antibodies are present in this patient?
- How are you evaluating the potential role of these antibodies in causing platelet refractoriness?
- What recommendations for further testing or management strategies are you including in your report?
- How are you tailoring your report to be informative and useful for a clinical colleague investigating this issue?
- Are you finding it straightforward to identify the relevant antibody specificities and their potential link to platelet refractoriness?
- How effective are you at accessing and interpreting the patient’s transfusion history and any previous platelet increment data?
- What challenges are you encountering in differentiating between HLA and HPA antibodies as potential causes?
- What are you learning about the immunological basis of platelet refractoriness and its investigation?
- If the antibody profile is complex with multiple specificities, how are you prioritising the most likely culprits?
- Are you considering other non-immunological causes of platelet refractoriness in your interpretation?
- What level of detail about specific antibody testing or selection of compatible platelets are you providing to the clinical colleague?
On action
- What aspects of the patient’s history suggested platelet refractoriness?
- What specific HLA and/or HPA antibodies were identified in the sensitised patient?
- How did you use this information to prepare your interpretive report for your clinical colleague?
- What recommendations did you include in your report to guide further investigation?
- What are the common causes of platelet refractoriness, including immunological factors?
- How does HLA and HPA antibody identification contribute to the investigation of platelet refractoriness?
- What are the strategies for managing patients with platelet refractoriness due to alloimmunisation?
- How can laboratory testing guide the selection of appropriate platelet units for these patients?
- How will you approach the interpretation of results for patients with suspected platelet refractoriness?
- What further knowledge do you need about HLA and HPA systems and their relevance to platelet transfusion?
- How will you communicate effectively with clinical colleagues to facilitate the investigation and management of platelet refractoriness?
Beyond action
- Have you reviewed the case of the sensitised patient and the interpretive report you prepared for the investigation of platelet refractoriness?
- Have you considered the subsequent clinical investigation and whether your report provided useful information?
- Did discussions with the clinical colleague provide further insight into the causes and management of platelet refractoriness?
- Has this training activity enhanced your understanding of the immunological aspects of platelet refractoriness, particularly in sensitised patients?
- How has this experience improved your ability to select appropriate tests and interpret their results in the context of investigating platelet refractoriness?
- Has it enhanced your communication skills with clinical colleagues regarding complex diagnostic investigations?
- How has this activity contributed to your ability to assess the suitability of patients for HLA/HPA selected platelets and identify compatible platelet units?
- Will the knowledge and skills gained in this training activity be valuable in future investigations of platelet refractoriness or in discussions with haematologists and transfusion practitioners?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 2 |
Outcome
Interpret and report tests across the range of techniques applied and provide appropriate clinical advice for solid organ transplant. |
| # 5 |
Outcome
Assess the suitability of patients for HLA/HPA selected platelets and identify compatible platelet units. |
| # 7 |
Outcome
Practice in accordance with quality management and accreditation standards. |
| # 8 |
Outcome
Practice effectively in partnership with service users, other clinical specialisms and the wider multidisciplinary team in the investigation of solid organ transplantation and platelet transfusion. |